|Issuer:||CRISPR THERAPEUTICS AG (CRSP)|
|Original Submission Date:|
KASINGER JAMES R.
C/O CRISPR THERAPEUTICS, INC.
105 W FIRST STREET BOSTON, MA 02127
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|RESTRICTED STOCK UNITS||0.0||2023-02-18||deemed execution date||M||3,825 (d)||common shares 3,825||$0.00||11,475||direct|
|f1||each restricted stock unit represents a contingent right to receive one share of crsp common shares.|
|f2||amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. this sale is mandated by the company's rsu settlement policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.|
|f3||this restricted stock unit award was granted on february 18, 2022 with respect to 15,300 common shares, with (i) one quarter of the shares vesting on february 18, 2023, (ii) one quarter of the shares vesting on february 18, 2024, (iii) one quarter of the shares vesting on february 18, 2025, and (iv) one quarter of the shares vesting on february 18, 2026.|